title: Prediction of response to imatinib in patients with chronic myelogenous leukemia by flow cytometric analysis of bone marrow blastic cell phenotypes.
authors.forename: Satoko
authors.initials: S
authors.lastname: Oka
authors.forename: Kazuo
authors.initials: K
authors.lastname: Muroi
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Matsuyama
authors.forename: Shin-ichiro
authors.initials: S
authors.lastname: Fujiwara
authors.forename: Iekuni
authors.initials: I
authors.lastname: Oh
authors.forename: Kazuya
authors.initials: K
authors.lastname: Sato
authors.forename: Satoru
authors.initials: S
authors.lastname: Kikuchi
authors.forename: Masuzu
authors.initials: M
authors.lastname: Ueda
authors.forename: Masaki
authors.initials: M
authors.lastname: Toshima
authors.forename: Takahiro
authors.initials: T
authors.lastname: Suzuki
authors.forename: Katsutoshi
authors.initials: K
authors.lastname: Ozaki
authors.forename: Tadashi
authors.initials: T
authors.lastname: Nagai
authors.forename: Keiya
authors.initials: K
authors.lastname: Ozawa
mesh_terms: D000328:Adult; D000368:Aged; D000941:Antigens / Q000276:immunology; D001549:Benzamides; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000276:immunology / Q000473:pathology*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000941:Antigens; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate